Marker Therapeutics, Inc.

News

Marker Therapeutics, Inc. Appoints Anthony H. Kim as Chief Financial Officer

“Over my career, I’ve had the chance to work with many great companies, a number of which have had a major impact within the biotech sector that led to great advances in patient care. However, I believe Marker Therapeutics’ patient data are truly exceptional, generating excellent complete response rates in a meaningful number of patients to date. ," said Mr. Kim.
Read More

DoD Awards $11M for Phase 2 Trial of TPIV110 Breast Cancer Therapy

The U.S. Department of Defense (DoD) has awarded Mayo Clinic researchers $11 million to conduct a Phase 2 trial investigating the TPIV110 vaccine, in combination with Herceptin (trastuzumab), as a therapy for women with HER2-positive breast cancer.
Read More

Marker Therapeutics to Present at Three Upcoming Healthcare Conferences

President and CEO, Peter L. Hoang, will be participating in several healthcare conferences this month.
Read More

Marker Therapeutics, Inc. Announces New Executive Appointments

"We are excited and fortunate to have these four highly accomplished professionals join our team,” commented Marker Therapeutics’ President & CEO Peter L. Hoang.
Read More

Marker Therapeutics: A Safer And Potentially More Effective CAR-T Alternative

The company is the product of a merger between TapImmune and Marker Therapeutics that completed on Oct 17th, 2018 and on Thursday, October 18th begins trading under the ticker (NASDAQ: MRKR), retiring TapImmune's ticker (TPIV).
Read More

Marker to Present at Two Upcoming Cellular Therapy Conferences

Marker Therapeutics, Inc. President and CEO, Peter L. Hoang, will be participating in conferences next week.
Read More

TapImmune and Marker Therapeutics Announce Successful Closing of Previously Announced Merger and Financing

“The closing of this merger marks a significant milestone, since the combined company is well-positioned to become a leader in cancer immunotherapy, with potentially transformative therapies,” said Peter Hoang, CEO of Marker Therapeutics, Inc. Learn more about Marker Therapeutics, Inc. by going to www.markertherapeutics.com
Read More

Mayo Clinic Lands $11 Million Grant to Study Breast Cancer Immunotherapy

The Department of Defense awarded more than $11 million for this Jacksonville study.
Read More

TapImmune’s HER2/neu-Targeted Breast Cancer Vaccine to be Studied in a Large Phase 2 Immunotherapy Combination Study Funded by an $11 Million U.S. Department of Defense Grant

Peter L. Hoang, President and CEO of TapImmune, stated, “I am delighted that the U.S. Department of Defense has again chosen to support our technology and therapeutic platform with another funding commitment.
Read More

TapImmune to Present at Two Upcoming Investor Conferences

Peter L. Hoang will be presenting at the 2018 Cantor Global Healthcare Conference and the Sachs Associates 18th Annual Biotech in Europe Forum. Webcast will be available for both events.
Read More